ASND vs. LEGN, ROIV, CERE, ITCI, VKTX, JAZZ, CYTK, CTLT, ELAN, and IONS
Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include Legend Biotech (LEGN), Roivant Sciences (ROIV), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Cytokinetics (CYTK), Catalent (CTLT), Elanco Animal Health (ELAN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "pharmaceutical preparations" industry.
Ascendis Pharma A/S (NASDAQ:ASND) and Legend Biotech (NASDAQ:LEGN) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
Ascendis Pharma A/S received 349 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 65.48% of users gave Ascendis Pharma A/S an outperform vote while only 63.33% of users gave Legend Biotech an outperform vote.
Ascendis Pharma A/S currently has a consensus price target of $173.25, suggesting a potential upside of 22.86%. Legend Biotech has a consensus price target of $82.64, suggesting a potential upside of 87.91%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Legend Biotech is more favorable than Ascendis Pharma A/S.
70.9% of Legend Biotech shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Legend Biotech. MarketBeat recorded 8 mentions for Ascendis Pharma A/S and 1 mentions for Legend Biotech. Ascendis Pharma A/S's average media sentiment score of 0.45 beat Legend Biotech's score of -0.49 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.
Ascendis Pharma A/S has a net margin of -180.61% compared to Legend Biotech's net margin of -181.75%. Legend Biotech's return on equity of -37.19% beat Ascendis Pharma A/S's return on equity.
Ascendis Pharma A/S has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.
Legend Biotech has lower revenue, but higher earnings than Ascendis Pharma A/S. Legend Biotech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Ascendis Pharma A/S beats Legend Biotech on 10 of the 18 factors compared between the two stocks.
Get Ascendis Pharma A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ascendis Pharma A/S Competitors List
Related Companies and Tools
